Pentasa (mesalazine) prolonged-release granules

Pentasa is a specialized pharmaceutical product used for the treatment of inflammatory bowel diseases like Crohn's disease and ulcerative colitis. The active ingredient, mesalazine (5-ASA), is delivered through a unique prolonged-release formulation developed to reach targeted areas of the intestine.

The brand was originally developed and patented by Ferring Pharmaceuticals, a company founded in Malmö, Sweden, and now headquartered in Saint-Prex, Switzerland. Ferring remains the global owner and primary manufacturer of Pentasa. While the brand is global, production occurs in specialized facilities across Europe, notably in Denmark and Switzerland, to serve international markets including Brazil. In Brazil, Ferring Pharmaceuticals operates its own local subsidiary to manage distribution and regulatory compliance.